Ondas Raises Q4 Revenue Outlook Ahead Of Earnings: ONDS Stock Rises Pre-Market

Published : Mar 09, 2026, 07:10 PM IST
https://stocktwits.com/news-articles/markets/equity/why-onds-stock-moving-revenue-guidance-raised/cZdVlVVRIIS

Synopsis

The drone and wireless technology firm reaffirmed its 2026 revenue guidance of $170 million to $180 million.

Shares of Ondas Holdings (ONDS) rose over 1% in pre-market trading on Monday after the company said it expects to report fourth-quarter revenue above its earlier forecast when it releases results on March 25.

For the fourth quarter of 2025, the company expects revenue between $29.1 million and $30.1 million, above earlier guidance of $27 million to $29 million. According to Fiscal.ai data, Wall Street expects a revenue of $27.5 million. Net loss is projected between $20.4 million and $20.9 million.

For the full year 2025, Ondas now expects revenue of $49.7 million to $50.7 million, also higher than its previous forecast and above Street estimates of just above $48 million. Ondas anticipates a full-year net loss of $52.8 million to $53.3 million.

Looking ahead, the drone and wireless technology firm reaffirmed its 2026 revenue guidance of $170 million to $180 million.

Get updates to this developing story on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<

PREV

Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.

Recommended Stories

Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Shares Continue To Draw Retail Buzz
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy